Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33144645" target="_blank" >RIV/61989592:15110/14:33144645 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3109/10428194.2013.850167" target="_blank" >http://dx.doi.org/10.3109/10428194.2013.850167</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2013.850167" target="_blank" >10.3109/10428194.2013.850167</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era

Popis výsledku v původním jazyce

Abstract This study analyzed the prognostic significance of sIL-2Ralfa levels in 100 prospectively enrolled patients with previously untreated follicular lymphoma. It showed that sIL-2Ralfa level ? 115 pmol/L at the time of treatment initiation correlates with the high FLIPI-2, bulky disease, advanced clinical stage, number of involved lymph nodes, bone marrow involvement and elevated beta-2 microglobulin (B2M) level. When testing all patients, sIL-2Ralfa ? 115 pmol/L was associated with significantly shorter progression-free (PFS; p{0.03, HR 2.04) but not overall (OS; p=0.06, HR 2.36) survival rates. Subanalysis of the CHOP+-rituximab patients showed higher predictive power for both PFS (HR 2.75, 95% CI 1.24-6.11, p=0.01,) and OS (HR 3.33, 95% CI 1.15-9.63, p=0.02,). In the whole population (n=100), only B2M proved a significant univariate predictor (p=0.007, HR = 2.8) of the PFS. When testing patients treated with CHOP+-rituximab, sIL-2Ralfa was found to be the best univariate predic

Název v anglickém jazyce

Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era

Popis výsledku anglicky

Abstract This study analyzed the prognostic significance of sIL-2Ralfa levels in 100 prospectively enrolled patients with previously untreated follicular lymphoma. It showed that sIL-2Ralfa level ? 115 pmol/L at the time of treatment initiation correlates with the high FLIPI-2, bulky disease, advanced clinical stage, number of involved lymph nodes, bone marrow involvement and elevated beta-2 microglobulin (B2M) level. When testing all patients, sIL-2Ralfa ? 115 pmol/L was associated with significantly shorter progression-free (PFS; p{0.03, HR 2.04) but not overall (OS; p=0.06, HR 2.36) survival rates. Subanalysis of the CHOP+-rituximab patients showed higher predictive power for both PFS (HR 2.75, 95% CI 1.24-6.11, p=0.01,) and OS (HR 3.33, 95% CI 1.15-9.63, p=0.02,). In the whole population (n=100), only B2M proved a significant univariate predictor (p=0.007, HR = 2.8) of the PFS. When testing patients treated with CHOP+-rituximab, sIL-2Ralfa was found to be the best univariate predic

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia & Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

1584-1590

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—